Loading clinical trials...
Loading clinical trials...
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for preven...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
NCT06920940 · Bipolar Disorder (BD), Bipolar Disorder NOS, and more
NCT06656416 · Bipolar Disorder I or II With a Major Depressive Episode
NCT06882590 · Bipolar Disorder I or II
NCT05964777 · Bipolar Disorder in Remission
NCT05705063 · Bipolar Disorder I, Bipolar II Disorder, and more
Pharmacovigilance Department
Osaka, Osaka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions